Page:United States Statutes at Large Volume 124.djvu/1005

 124 STAT. 979 PUBLIC LAW 111–148—MAR. 23, 2010 Cosmetic Act) that, in the determination of the Director of NIH— ‘‘(A) is a priority to diagnose, mitigate, prevent, or treat harm from any disease or condition; and ‘‘(B) for which the incentives of the commercial market are unlikely to result in its adequate or timely development. ‘‘(4) MEDICAL PRODUCT.—The term ‘medical product’ means a drug, device, biological product, or product that is a combina- tion of drugs, devices, and biological products. ‘‘(b) ESTABLISHMENT OF THE CURES ACCELERATION NETWORK.— Subject to the appropriation of funds as described in subsection (g), there is established within the Office of the Director of NIH a program to be known as the Cures Acceleration Network (referred to in this section as ‘CAN’), which shall— ‘‘(1) be under the direction of the Director of NIH, taking into account the recommendations of a CAN Review Board (referred to in this section as the ‘Board’), described in sub- section (d); and ‘‘(2) award grants and contracts to eligible entities, as described in subsection (e), to accelerate the development of high need cures, including through the development of medical products and behavioral therapies. ‘‘(c) FUNCTIONS.—The functions of the CAN are to— ‘‘(1) conduct and support revolutionary advances in basic research, translating scientific discoveries from bench to bed- side; ‘‘(2) award grants and contracts to eligible entities to accel- erate the development of high need cures; ‘‘(3) provide the resources necessary for government agen- cies, independent investigators, research organizations, bio- technology companies, academic research institutions, and other entities to develop high need cures; ‘‘(4) reduce the barriers between laboratory discoveries and clinical trials for new therapies; and ‘‘(5) facilitate review in the Food and Drug Administration for the high need cures funded by the CAN, through activities that may include— ‘‘(A) the facilitation of regular and ongoing communica- tion with the Food and Drug Administration regarding the status of activities conducted under this section; ‘‘(B) ensuring that such activities are coordinated with the approval requirements of the Food and Drug Adminis- tration, with the goal of expediting the development and approval of countermeasures and products; and ‘‘(C) connecting interested persons with additional tech- nical assistance made available under section 565 of the Federal Food, Drug, and Cosmetic Act. ‘‘(d) CAN BOARD.— ‘‘(1) ESTABLISHMENT.—There is established a Cures Accel- eration Network Review Board (referred to in this section as the ‘Board’), which shall advise the Director of NIH on the conduct of the activities of the Cures Acceleration Network. ‘‘(2) MEMBERSHIP.— ‘‘(A) IN GENERAL.— ‘‘(i) APPOINTMENT.—The Board shall be comprised of 24 members who are appointed by the Secretary and who serve at the pleasure of the Secretary. Grants. Contracts.